

4.26 (1.53) cm/year. After the first 52 weeks of treatment, mean (SD) AGV was 5.67 (0.98) cm/year. Mean (SD) AGV over the second year was 5.57 (1.10) cm/year. Mean (SD) change from baseline in height Z-score improved by +0.24 (0.31) at Week 52 in the pivotal study and +0.45 (0.56) at Week 52 in the extension study. Mean (SD) upper-to-lower body segment ratio improved with a change from baseline of -0.03 (0.11) at Week 52 in the pivotal study and -0.09 (0.11) at Week 52 in the extension study. In children who switched from placebo to vosoritide after 52 weeks, baseline AGV was 4.06 (1.20) cm/year and 3.94 (1.07) cm/year after 52 weeks on placebo. In the second year, after receiving 52 weeks of vosoritide, mean AGV was 5.65 (1.47) cm/year, the mean (SD) change in height Z-score was +0.24 (0.34), and the change in upper-to-lower body segment ratio was -0.03 (0.08). No new adverse events associated with vosoritide treatment were detected with up to 2 years of continuous daily, subcutaneous treatment. Most adverse events were mild and no serious adverse events were attributed to vosoritide. The most common adverse event remains mild and transient injection site reactions. **Conclusions:** The effect of vosoritide administration on growth as measured through AGV and height Z-score was maintained for up to 2-years in children with achondroplasia aged 5 to 18 years, with an improvement of body proportions.

Pediatric Endocrinology

EMERGING ENDOCRINE THERAPIES ACROSS THE LIFESPAN

Primary Results From MATCH: A Randomised Controlled Trial in Primary Aldosteronism

Xilin Wu, BA MBBS MRCP(London)¹, Russell Senanayake, MSc MRCP², Emily Goodchild, BMBS BSc¹, Wael Bashari, MBBS, MSc, MRCP(UK)², Jackie Salsbury, MSc¹, Giulia Argentesi, BMBS MSc MRCP¹, Samuel M. O'Toole, MB BChir PhD¹, Matthew Matson, FRCP³, Laila Parvanta, FRCS³, Alison Marker, FRCPATH⁴, Daniel Berney, FRCPATH³, Anju Sadhev, MB BS, MRCP, FRCP³, Nicholas Bird, MA MSc PhD⁴, Alexander McConnachie, PhD⁵, Kate Laycock, MBBS BMedSci(hons) MRCP¹, Alasdair McIntosh, PhD⁵, Kennedy Cruickshank, MBChB, MD, FRCP⁶, Heok Cheow, FRCP⁷, Mark Gurnell, MBBS MA (Med Ed), PhD, FRCP², William M. Drake, DM FRCP³, Morris J. Brown, MD, FRCP, FMedSci¹.

¹Queen Mary University of London, London, United Kingdom, ²University of Cambridge, Cambridge, United Kingdom, ³Barts Health, London, United Kingdom, ⁴Cambridge University NHS Foundation Trust, Cambridge, United Kingdom, ⁵University of Glasgow, Glasgow, United Kingdom, ⁶Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷University of Cambridge NHS Foundation Trust, Cambridge, United Kingdom.

Primary aldosteronism (PA) is now considered the sole, often curable, cause of hypertension in 5-10% of patients. Yet there has been only one RCT, and practice has changed little since the advent of CT scanning. Adrenal vein sampling (AVS) and adrenalectomy remain the standard, invasive interventions, leading to a 50% reduction in pill count as the average clinical improvement. **Study Design** In MATCH (*Is Metomidate PET-CT superior to Adrenal vein sampling in predicting outcome from adrenalectomy in*

patients with primary Hyperaldosteronism), 142 patients, mean age 52, 32% female, 32% of African ancestry, 46% hypokalemic, had both AVS and 11C-metomidate PET CT (MTO) in random order, and were referred for surgery if aldosterone/cortisol ratio differed >4-fold between adequately cannulated adrenal veins, and/or SUVmax on MTO was >1.25 higher, in a definite tumour, than the opposite adrenal. The primary outcome is the proportion of patients in whom adrenalectomy achieved complete or partial biochemical or clinical cure, analysed hierarchically using PASO criteria.¹ Anticipating ~50% incidence of unilateral PA, MATCH is powered to detect 25% superiority of MTO vs AVS, or non-inferiority at a lower-bound CI of -17%. Secondary outcomes include non-randomised comparison of outcomes between unilateral and bilateral PA; prediction of clinical outcome from the home BP (12 readings over 3 days) before and after starting spironolactone 100 mg od for 4 weeks; quality-of-life assessments; and analyses, by RNAseq, of genotype and transcriptomes of 56 of the CYP11B2-positive tumors, correlated with ethnicity and outcomes. **Results:** The analysis set is 75 patients who, on 31 Dec 2020, had undergone adrenalectomy with > 6 months follow-up. 67 patients (89%) had complete biochemical cure following PASO criteria,¹ and 63 (84%) had complete or partial clinical cure. In 39 of the surgical patients, only one of MTO or AVS was scored as high-probability using criteria above. This score was confirmed at the multi-centre, Multi-Disciplinary Team (MDT) meeting which reviewed all MTO scans without knowledge of AVS. In the primary analysis, comparing accuracy of MTO and AVS by McNemar test, the 39 discordant results were allocated as a win to the positive investigation, if the patient was cured, or to the negative investigation, if not cured. 50/56 CYP11B2-positive tumors had a known mutation; the frequency was *CACNA1D>KCNJ5>ATP1A1>ATP2B3>CTNNB1>GNAQ>CLCN2*, differing between patients whose hypertension was completely or partially cured. Two other tumors had novel gene mutations. Several RNAseq transcripts varied with genotype and outcome, including some encoding measurable, secreted proteins. Full primary and secondary outcomes will be presented.

1. Williams TA, et al. *Lancet Diabetes Endocrinol.* 2017;5:689-699

Pediatric Endocrinology

EMERGING ENDOCRINE THERAPIES ACROSS THE LIFESPAN

Safety Evaluation of the Omnipod® 5 Automated Insulin Delivery System Over Three Months of Use in Adults and Adolescents With Type 1 Diabetes (T1D)

Sue A. Brown, MD¹, Carol J. Levy, MD, CDE², Irl B. Hirsch, MD³, Bruce W. Bode, MD⁴, Anders L. Carlson, MD⁵, Viral N. Shah, MD⁶, Jordan E. Pinsker, MD⁷, Ruth S. Weinstock, MD, PhD⁸, Anuj Bhargava, MD, MBA, CDE, FACP, FACE⁹, Sanjeev N. Mehta, MD, MPH¹⁰, Lori M. Laffel, MD, MPH¹⁰, Thomas C. Jones, MD, FACE¹¹, Jennifer L. Sherr, MD, PhD¹², Grazia Aleppo, MD, FACE, FACP¹³, Gregory P. Forlenza, MD, MS¹⁴, Trang T. Ly, MBBS FRACP PhD¹⁵.

¹University of Virginia, Charlottesville, VA, USA, ²Mount Sinai School of Medicine, New York, NY, USA, ³University of Washington School of Medicine, Seattle, WA, USA, ⁴Atlanta